Table of Contents
Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Personalized Medicine Return on Investment: What' s In It for Me?
- Expert Commentary - How to Advance the Concept of Personalized Healthcare
and
- Integrate It into Standard Medical Practice
- Integrating Diagnostics into Drug Development
- The Ideal Organizational Structure for a Personalized Medicine Endeavor
- Championing Personalized Medicine
- Deal Structures Between the Diagnostics and Pharmaceutical Companies
- Addressing Policy Issues Related to Personalized Healthcare
- Does Personalized Medicine Improve Healthcare and Reduce Cost?
- Educating the Care Delivery Community
- Mining Prescription Claims Databases to Advance Personalized Medicine
- Medco Health Solutions
- Striking Gold in PBM Prescription Claim Databases
- New Business Opportunities and Strategies for PBM Companies
- Generic and Biosimilar Drugs
- Diagnostic Testing
- Pharmacogenomics
- Value-Added Clinical Opportunity
- R&D Pipeline and Clinical Programs
- Mayo Clinic Collaboration
- LabCorp and Indiana University Collaboration
- Drug Interactions Between Plavix and Proton Pump Inhibitors
- Member Genotyping Program
- Expert Commentary - Clinical Predictive Guides: Novel Enrichment
Strategies Create
- New Partnering Opportunities
- Clinical Predictive Rules - Diagnostic and Treatment Algorithms
- Validated CPGs
- Opportunities in Diagnostics and Drug Development
- Diagnostics
- Drug Development
- Evolving Partnering Opportunities
- Clinical Trial Enrichment - Global Phenotype Mapping
- Infl uencing Physician Behavior
- Nexus Between Personalized Healthcare and Information Privacy
Tables
- 1. Personalized Medicine Return on Investment: Two Studies on Newly
Diagnosed Breast Cancer
- 2. Medco' s R&D Pipeline and Client Clinical Programs
- 3. Select Clinical Prediction Rules
- 4. Phenotype Mapping: Subgroups of Patients with Post-Traumatic Stress
Disorder
Figures
- 1. Personalized Medicine Coalition
- 2. Major Issues in Integrating Diagnostics into Therapeutic Development
- 3. Deal Timeline: Multiple Diagnostic Partners and Different Deal
Structures
- 4. How Government Can Accelerate Adoption of Personalized Medicine
- 5. Medco Therapeutic Resource Centers
- 6. Value Proposition for Pharmacy Benefi t Management Clients
- 7. Clinical Prediction Rules: Development and Validation Trends
- 8. Evolution of Diabetes Mellitus: Classifi cation of Disease
Experts Featured
- Todd A. Hoover, M.D., Vice President, and Paul Herscu, N.D., Chief Science
Offi cer,
- Personalized Pharmaceutical Systems
- Wayne A. Rosenkrans, Jr., Ph.D. Chairman and President, Personalized
Medicine Coalition
|
Related Report
|
View Cart
